Clinical trials: IGA Nephropathy
Lupus Nephritis, IgA Nephropathy
The Correlation of Periostin and Renal Pathology in Chronic Kidney Disease Patients
The purpose of this study is to determine the location of periostin and urine periostin level in patients with lupus nephritis and IgA nephropathy.
- Trial name
- NCT02493101
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Chulalongkorn University
Immunoglobulin a Nephropathy
A Study of the Effect and Safety of HS-10390 in the Treatment of Patients with Primary IgA Nephropathy
This study will evaluate the efficacy and safety of HS-10390 in subjects with primary IgA nephropathy, and explore the optimal dose for the treatment.
- Trial name
- NCT06635772
- Testing
- HS-10390, Irbesartan
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Hansoh BioMedical R&D Company
IgA Nephropathy (IgAN), Early Initial Therapy
A Multi-center Open Label Prospective Study on Early Initiation of Targeted-release Formulation of Budesonide in Patients With Primary IgA Nephropathy
To observe of the efficacy and safety of early initiation of budesonide enteric coated capsules in the treatment of primary IgA nephropathy.
- Trial name
- NCT06676007
- Testing
- Gd-IgA1 test
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Sichuan Provincial People's Hospital
Autoimmune Diseases, SLE - Systemic Lupus Erythematosus
RD06-05 Universal CD19/BCMA CAR-T for Refractory Pediatric Autoimmune Diseases
This is a single-arm, open-label, phase I clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of RD06-05, a universal CD19/BCMA dual-targeting chimeric antigen receptor T-cell…
- Conditions
- Autoimmune Diseases, SLE - Systemic Lupus Erythematosus, SSc-Systemic Sclerosis, IIM- Idiopathic Inflammatory Myopathies
- Trial name
- NCT07674147
- Testing
- RD06-05 CART Cell Infusion
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- The Children's Hospital of Zhejiang University School of Medicine
IgA Nephropathy, Membranous Nephropathy
IM19 CAR-T Cell Therapy for IgA Nephropathy Patients and Membranous Nephropathy Patients
IM19 CAR-T cell therapy for IgA nephropathy patients with urinary protein and renal dysfunction, as well as patients with intermediate to high-risk primary membranous nephropathy
- Trial name
- NCT06690359
- Testing
- IM19 chimeric antigen receptor T cell injection
- Volunteers
- 12 people
- Sponsor
- Beijing Immunochina Medical Science & Technology Co., Ltd.
IgA Nephropathy, Lupus Nephritis
Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies
This is a Phase II trial assessing the safety and preliminary efficacy of daily APL-2 subcutaneous infusion administered for 16 weeks with a 6 month safety follow up, in patients with glomerulopathies
- Conditions
- IgA Nephropathy, Lupus Nephritis, Membranous Nephropathy, C3 Glomerulonephritis
- Trial name
- NCT03453619
- Testing
- APL-2
- Where
- 17 sites in United States
- Volunteers
- 21 people
- Sponsor
- Apellis Pharmaceuticals, Inc.
IgA Nephropathy, Glomerular Diseases
IgA Nephropathy Biomarkers Evaluation Study (INTEREST)
This prospective cohort study is designed to examine the association between blood and urine biomarkers (including genetic variants) and long-term kidney disease progression among 2000 Chinese IgA nephropathy patients with…
- Trial name
- INTEREST (NCT02954419)
- Testing
- No intervention
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Sun Yat-sen University
IgA Nephropathy
An Observational Study of IgA Nephropathy: Pathological Variants and Clinical Data
The pathological variants of IgA nephropathy identified by the Oxford classification may be related to the clinical data at presentation and follow-up, including proteinuria and renal function.
- Trial name
- NCT01502579
- Where
- China
- Volunteers
- 603 people
- Sponsor
- Guangdong Provincial People's Hospital
IGA Nephropathy
Validity and Security of Reh-acteoside Therapy for Patients of IgA Nephropathy
This prospective, randomized, controlled, multi-center clinical trial will evaluate the effect and security of reh-acteoside therapy for patients of IgA nephropathy.
- Trial name
- NCT02662283
- Testing
- Prednisolone, Reh-acteoside
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Sun Yat-sen University
Proteinuria
The Effects of Weight Reduction in IgA Nephropathy
The study aims to explore the non-pharmacological treatment of IgA nephropathy by weight reduction. The investigators hypothesized that benefits of weight loss may reduce proteinuria.
- Trial name
- WeightPro (NCT01773382)
- Testing
- weight reduction
- Where
- Thailand
- Volunteers
- 30 people
- Sponsor
- Chulalongkorn University
Cancer
Wormwood in Chronic Progressive Disorders With Reduced Appetite
Wormwood is approved herbal medicine for the treatment of reduced appetite in Germany (Registration No.: 1339.99.99). Reduced appetite is observed in many chronic health disorders such as old age, immune disorders and cancer.
- Trial name
- NCT01126931
- Where
- Germany
- Volunteers
- 300 people
- Sponsor
- University Hospital Freiburg
IgA Nephropathy, ESRD
TESTING -ON Post-Trial ObservatioNal Cohort Study
The primary aim of this study is to extend follow up of TESTING study participants and to assess the long-term effects of a 6-9-month course of oral methylprednisolone on End Stage Kidney Disease (ESKD), according to dose…
- Conditions
- IgA Nephropathy, ESRD, Glomerulonephritis, Kidney Diseases
- Trial name
- TESTING-ON (NCT05434325)
- Where
- 59 sites in Australia, Canada and 4 more
- Volunteers
- 211 people
- Sponsor
- The George Institute
Immunoglobulin A Nephropathy, Kidney Diseases
A Study of the Safety and Activity of Sparsentan for the Treatment of Patients With Immunoglobulin A Nephropathy
To determine the nephroprotective potential of treatment with sparsentan in (1: Cohort A) patients newly-diagnosed with immunoglobulin A nephropathy (IgAN) (ie, incident patients) who have not received prior…
- Conditions
- Immunoglobulin A Nephropathy, Kidney Diseases, Glomerulonephritis, IGA, Glomerulonephritis
- Trial name
- SPARTAN (NCT04663204)
- Testing
- Sparsentan
- Where
- 6 sites in United Kingdom
- Volunteers
- 24 people
- Sponsor
- University of Leicester
Lupus Nephritis, Immunoglobulin A Nephropathy
Study of ALXN2050 in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)
This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter study of ALXN2050 (120 and 180 milligrams [mg]) in addition to background therapy consistent with the standard of care in adult participants (≥ 18 to ≤…
- Conditions
- Lupus Nephritis, Immunoglobulin A Nephropathy, IgAN, LN
- Trial name
- NCT05097989
- Testing
- ALXN2050
- Where
- 71 sites in United States, Argentina and 14 more
- Volunteers
- 100 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Primary IgA Nephropathy
A Study of RC18 Administered Subcutaneously to Subjects With Primary IgA(Immunoglobulin A) Nephropathy
To evaluate the safety and efficacy of Tai Ai(Recombinant Human B Lymphocyte Stimulator Receptor-Antibody Fusion Protein for Injection) in the treatment of IgA nephropathy.
- Trial name
- NCT04291781
- Testing
- RC18 160mg, RC18 240mg
- Where
- China
- Volunteers
- 44 people
- Sponsor
- RemeGen Co., Ltd.
IgA Nephropathy
Efficacy and Safety of Omega-3 Fatty Acids(Omacor®) for the Treatment of Immunoglobulin A Nephropathy
The purpose of this study is to compare omega-3 fatty acids with placebo for efficacy in retardation of increase of serum creatinine(SCr) in IgA Nephropathy
- Trial name
- IgAN (NCT00549692)
- Testing
- Omega-3 fatty acid ethylester90
- Where
- 5 sites in South Korea
- Volunteers
- 152 people
- Sponsor
- Kuhnil Pharmaceutical Co., Ltd.
IgA Nephropathy
Aliskiren for Proteinuric IgAN Despite Angiotensin Blockade
Study objective: To investigate the potential anti-proteinuric efficacy of aliskiren, a novel direct renin inhibitor (DRI), in addition to angiotensin receptor blocker (ARB) in immunoglobulin A nephropathy (IgAN) patients at risk…
- Trial name
- NCT00922311
- Testing
- Aliskiren
- Where
- 2 sites in China
- Volunteers
- 25 people
- Sponsor
- The University of Hong Kong
IgA Nephropathy
Study of ARO-CFB in Adult Healthy Volunteers
The purpose of AROCFB-1001 is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of ARO-CFB Injection in adult healthy volunteers (HVs). HVs will receive either one or two doses of ARO-CFB or placebo.
- Trial name
- NCT06209177
- Testing
- ARO-CFB
- Where
- New Zealand
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Arrowhead Pharmaceuticals
Glomerulonephritis, Immunoglobulin A (IgA)
Beginning of Effective and Safe Treatment in Immunoglobulin A-1 Nephropathy-1
Immunoglobulin A nephropathy (IgAN) is the most common glomerulonephritis worldwide. IgAN is progressive, particularly when patients have a significant proteinuria (proteinuria >1g/g creatinine), impaired kidney function, or…
- Trial name
- BEST-IgAN-1 (NCT03357653)
- Testing
- Losartan group
- Volunteers
- 174 people
- Sponsor
- Ewha Womans University
Focal Segmental Glomerulosclerosis, Immunoglobulin A Nephropathy
Humanistic Burden of (FSGS) Focal Segmental Glomerulosclerosis and IgAN (Immunoglobulin A Nephropathy)
The aim of this observational study is to assess humanistic burden among adults and children/adolescents with FSGS and IgAN as well as the burden and impact for patient care-partners in six countries (United States [US], United…
- Trial name
- HONUS (NCT05200871)
- Where
- 6 sites in United States, Germany and 1 more
- Volunteers
- 487 people
- Sponsor
- Travere Therapeutics, Inc.